Clinical Focus in SCLC: Emerging Insights on B7-H3–Targeted ADCs and Their Transformative Potential in Clinical Practice

Enhance your understanding of the rationale for integrating antibody–drug conjugates (ADCs) targeting B7-H3 into the treatment of small-cell lung cancer (SCLC) to better educate patients, caregivers, and colleagues and gain insight into clinical trials on these agents through a podcast, a text module with accompanying downloadable slides, and an expert ClinicalThought commentary.

Share

Program Content

Activities

B7-H3 SCLC
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: April 28, 2025

Expires: October 27, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.